FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
0.3349
-0.0026 (-0.77%)
At close: Jan 16, 2026, 4:00 PM EST
0.3365
+0.0016 (0.48%)
After-hours: Jan 16, 2026, 7:59 PM EST
Company Description
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications.
The company was founded in 2021 and is based in Houston, Texas.
FibroBiologics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 31, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Peter O’Heeron |
Contact Details
Address: 455 East Medical Center Boulevard, Suite 300 Houston, Texas 77598 United States | |
| Phone | 281 651 5150 |
| Website | fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $30.00 |
| CIK Code | 1958777 |
| CUSIP Number | 31573L105 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
| Jason D. Davis CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 2, 2026 | 8-K | Current Report |
| Dec 30, 2025 | EFFECT | Notice of Effectiveness |
| Dec 30, 2025 | 424B3 | Prospectus |
| Dec 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 29, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 23, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Dec 18, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 16, 2025 | D | Notice of Exempt Offering of Securities |
| Dec 15, 2025 | 8-K | Current Report |